Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
Autore:
Ljungman, P; Deliliers, GL; Platzbecker, U; Matthes-Martin, S; Bacigalupo, A; Einsele, H; Ullmann, J; Musso, M; Trenschel, R; Ribaud, P; Bornhauser, M; Cesaro, S; Crooks, B; Dekker, A; Gratecos, N; Klingebiel, T; Tagliaferri, E; Ullmann, AJ; Wacker, P; Cordonnier, C;
Indirizzi:
Huddinge Univ Hosp, Dept Hematol, SE-14186 Stockholm, Sweden Huddinge UnivHosp Stockholm Sweden SE-14186 SE-14186 Stockholm, Sweden St Anna Kinderspital, Vienna, Austria St Anna Kinderspital Vienna Austria Anna Kinderspital, Vienna, Austria Hop St Louis, Paris, France Hop St Louis Paris FranceHop St Louis, Paris, France Hop Archet, Nice, France Hop Archet Nice FranceHop Archet, Nice, France Hop Henri Mondor, F-94010 Creteil, France Hop Henri Mondor Creteil France F-94010 Mondor, F-94010 Creteil, France Univ Hosp, Dresden, Germany Univ Hosp Dresden GermanyUniv Hosp, Dresden, Germany Univ Tubingen Hosp, Tubingen, Germany Univ Tubingen Hosp Tubingen Germany iv Tubingen Hosp, Tubingen, Germany Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany Univ Munich Munich Germany D-8000 um Grosshadern, D-8000 Munich, Germany Univ Hosp, Essen, Germany Univ Hosp Essen GermanyUniv Hosp, Essen, Germany Univ Mainz, D-6500 Mainz, Germany Univ Mainz Mainz Germany D-6500Univ Mainz, D-6500 Mainz, Germany Osped Maggiore, Milan, Italy Osped Maggiore Milan ItalyOsped Maggiore, Milan, Italy Osped San Martino, Genoa, Italy Osped San Martino Genoa ItalyOsped San Martino, Genoa, Italy Univ Hosp Palermo, Palermo, Italy Univ Hosp Palermo Palermo ItalyUniv Hosp Palermo, Palermo, Italy Univ Hosp, Padua, Italy Univ Hosp Padua ItalyUniv Hosp, Padua, Italy Univ Utrecht Hosp, Utrecht, Netherlands Univ Utrecht Hosp Utrecht Netherlands trecht Hosp, Utrecht, Netherlands Univ Geneva, Hop Cantonal, CH-1211 Geneva, Switzerland Univ Geneva Geneva Switzerland CH-1211 onal, CH-1211 Geneva, Switzerland Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England Newcastle Gen Hosp Newcastle Upon Tyne Tyne & Wear England NE4 6BE ngland
Titolo Testata:
BLOOD
fascicolo: 2, volume: 97, anno: 2001,
pagine: 388 - 392
SICI:
0006-4971(20010115)97:2<388:CFCIAD>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; INTRAVENOUS IMMUNE GLOBULIN; ANTIVIRAL THERAPY; CMV INFECTIONS; RISK-FACTORS; CONTROLLED TRIAL; VIRUS PNEUMONIA; GANCICLOVIR; FOSCARNET; RETINITIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Ljungman, P Huddinge Univ Hosp, Dept Hematol, SE-14186 Stockholm, Sweden Huddinge Univ Hosp Stockholm Sweden SE-14186 ockholm, Sweden
Citazione:
P. Ljungman et al., "Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients", BLOOD, 97(2), 2001, pp. 388-392

Abstract

A retrospective study was performed to collect information regarding efficacy and toxicity of cidofovir (CDV) in allogeneic stem cell transplant patients. Data were available on 82 patients. The indications for therapy were cytomegalovirus (CMV) disease in 20 patients, primary preemptive therapy in24 patients, and secondary preemptive therapy in 38 patients. Of the patients, 47 had received previous antiviral therapy with ganciclovir, foscarnet, or both drugs. The dosage of CDV was 1 to 5 mg/kg per week followed by maintenance every other week in some patients. The duration of therapy rangedfrom 1 to 134 days (median, 22 days). Ail patients received probenecid andprehydration. Ten of 20 (50%) patients who were treated for CMV disease (9of 16 with pneumonia) responded to CDV therapy, as did 25 of 38 (66%) patients who had failed or relapsed after previous preemptive therapy and 15 of24 (62%) patients in whom CDV was used as the primary preemptive therapy. Of the patients, 21 (25.6%) developed renal toxicity that remained after cessation of therapy in 12 patients. Fifteen patients developed other toxicities that were potentially due to CDV or the concomitantly given probenecid. No toxicity was seen in 45 (61.6%) patients. Cidofovir can be considered as second-line therapy in patients with CMV disease failing previous antiviral therapy. However, additional studies are needed before CDV can be recommended for preemptive therapy. (C) 2001 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/07/20 alle ore 01:00:54